UNSPSC 51391718: Isoetarine or isoetharine

This classification denotes a bronchodilator and beta-adrenergic agonist with the molecular formula C13H21NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YV0SN3276Q, chemically known as 3,4-dihydroxy-alpha-(1-(isopropylamino)propyl)benzyl alcohol but generally known as isoetarine, which bears US NIH Compound Identifier 3762. European Medicines Agency schedules Isoetarine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08316MIG.

UNSPSC 51391718 Isoetarine or isoetharine is a Commodity code that in recent state and local procurement shows minimal alignment with its nominal pharmaceutical scope. The two recent opportunities tagged to this code — Seminole County's procurement of naloxone and drug deactivation systems, and the Texas Health and Human Services Commission's Request for Information on direct-to-manufacturer prescription programs — address broader pharmaceutical supply and pharmacy benefit management rather than the specific bronchodilator agent the code names. State and local governments do purchase pharmaceutical products and pharmacy services, but the recent activity under this code does not demonstrate a consistent buying pattern tied to isoetharine itself. Issuing bodies include county health departments and state health and human services agencies; the Seminole County opportunity reflects a community health initiative focused on opioid response and drug safety, while the Texas RFI represents exploratory procurement by a large state health agency seeking to reshape prescription fulfillment relationships.

Activity appears concentrated in Florida and Texas. The Seminole County IFB (Solicitation Number IFB60459723LAS) posted June 30, 2026, with a response deadline of July 26, 2023, seeks annual delivery of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly shipments to the Seminole County Community Health Building in Sanford, Florida; vendors must include shipping and delivery costs and comply with drug-free workplace and E-Verify requirements, with an initial two-year contract term and one-year renewal option. The Texas HHS RFI (Solicitation Number HHS0017013) posted April 3, 2026, is preliminary market intelligence gathering rather than a competitive bid, seeking vendor capabilities for direct prescription contracting between state agencies and manufacturers outside traditional pharmacy benefit manager channels. The mismatch between the code's pharmaceutical-agent scope and the actual work being solicited suggests this code may not be the most reliable filter for opportunities in pharmaceutical supply, health-benefit management, or drug-procurement programs at the state and local level.